Viewing Study NCT07086651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2025-12-25 @ 9:34 PM
Study NCT ID: NCT07086651
Status: COMPLETED
Last Update Posted: 2025-12-08
First Post: 2025-07-18
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Sponsor: Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castration Sensitive Prostate Cancer (mCSPC) View
None Cancer of the Prostate View
None Prostate Neoplasms View
None Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None enzalutamide View
None Xtandi View
None apalutamide View
None Erleada View
None mCSPC View
None metastatic castration-sensitive prostate cancer View
None treatment duration View
None metastatic hormone-sensitive prostate cancer View
None mHSPC View